Rasador Ana Caroline D, Balthazar da Silveira Carlos A, Pereira Natália P, Nogueira Raquel, Malcher Flavio, Lima Diego Laurentino
Dignity Health, St. Joseph's Hospital, Phoenix, AZ, 85013, USA.
Hospital Alemão Oswaldo Cruz, São Paulo, SP, 01323-020, Brazil.
Hernia. 2025 Mar 12;29(1):113. doi: 10.1007/s10029-025-03305-y.
Postoperative pain remains a common concern following ventral hernia repair (VHR), especially for open procedures. We aim to assess the effectiveness of the Transversus Abdominis Plane (TAP) block for the management of postoperative pain following VHR.
Cochrane, EMBASE, and PubMED, MEDLINE, and Web of Science were systematically searched for studies comprising adults undergoing VHR with preoperative TAP block, compared to placebo and epidural analgesia. The outcomes selected for analysis were postoperative pain with the numeric rating scale (NRS), postoperative morphine milligram equivalents (MME) per day, and hospital length of stay (LOS). Subgroup analysis was performed for studies using the Liposomal Bupivacaine (Exparel) for TAP block.
1,460 results were screened, and 14 included, comprising 9 retrospective cohort studies and 5 RCTs, totaling 1,617 patients. TAP block was associated with a shorter LOS compared to conventional pain measures (MD -1,14 days; 95% CI -2.05, -0.22; P = 0.014) and to epidural analgesia (MD -2.02 days; 95% CI -2.67, -1.37; P < 0.001), and lower NRS scale in the day of surgery (MD -1.24; 95% CI -1.81, -0.68; P < 0.001) and in the POD1 (MD -0.63; 95% CI -1.18, -0.08; P = 0.025) compared to placebo. No benefit was seen for TAP block regarding opioid consumption compared to epidural analgesia and placebo. No differences were seen between TAP block and epidural analgesia for the NRS scores. Subgroup analysis of Exparel compared to simple bupivacaine showed no benefit for Exparel.
The TAP block is associated with shorter LOS compared to placebo and epidural analgesia and is related to less early postoperative pain compared to the conventional pain measures. The TAP block should be considered as a pain management modality for VHR, however cost-effective analysis is required to address the feasibility of the routine utilization of this approach and to balance the financial benefits of its application.
腹疝修补术(VHR)后,术后疼痛仍是一个常见问题,尤其是开放手术。我们旨在评估腹横肌平面(TAP)阻滞对VHR术后疼痛管理的有效性。
系统检索Cochrane、EMBASE、PubMED、MEDLINE和Web of Science数据库,查找纳入接受术前TAP阻滞的VHR成年患者的研究,并与安慰剂和硬膜外镇痛进行比较。选择用于分析的结局指标为采用数字评分量表(NRS)评估的术后疼痛、术后每日吗啡毫克当量(MME)以及住院时间(LOS)。对使用脂质体布比卡因(Exparel)进行TAP阻滞的研究进行亚组分析。
共筛选出1460项结果,纳入14项研究,包括9项回顾性队列研究和5项随机对照试验,共计1617例患者。与传统疼痛措施相比,TAP阻滞与较短的住院时间相关(MD -1.14天;95%CI -2.05,-0.22;P = 0.014),与硬膜外镇痛相比也与较短的住院时间相关(MD -2.02天;95%CI -2.67,-1.37;P < 0.001),并且与安慰剂相比,手术当天(MD -1.24;95%CI -1.81,-0.68;P < 0.001)和术后第1天(POD1)(MD -0.63;95%CI -1.18,-0.08;P = 0.025)的NRS评分更低。与硬膜外镇痛和安慰剂相比,TAP阻滞在阿片类药物消耗方面未见益处。TAP阻滞和硬膜外镇痛在NRS评分方面未见差异。与单纯布比卡因相比,Exparel的亚组分析显示Exparel无益处。
与安慰剂和硬膜外镇痛相比,TAP阻滞与较短的住院时间相关,并且与传统疼痛措施相比,术后早期疼痛更少。TAP阻滞应被视为VHR的一种疼痛管理方式,然而需要进行成本效益分析,以探讨这种方法常规应用的可行性,并平衡其应用的经济效益。